Provencher, Diane

ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas

Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine

Chromatin Remodeling and CancerOvarian cancer diagnosis and treatment

Cited by 1,712

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence

Fleury, H., Malaquin, N., Tu, V., Gilbert, S., Martinez, A., Olivier, M.-A., Sauriol, S. A., Communal, L., Leclerc-Desaulniers, K., Carmona, E., et al. (2019) · Nature Communications

PARP inhibition in cancer therapyTelomeres, Telomerase, and Senescence

Cited by 228

Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)

Zietarska, M., Maugard, C. M., Filali‐Mouhim, A., Alam‐Fahmy, M., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2007) · Molecular Carcinogenesis

Ovarian cancer diagnosis and treatmentCancer Cells and Metastasis

Cited by 209

Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy

Astolfi, M., Péant, B., Lateef, M. A., Rousset, N., Kendall-Dupont, J., Carmona, E., Monet, F., Saad, F., Provencher, D., Mes-Masson, A.-M., et al. (2016) · Lab on a Chip

3D Printing in Biomedical ResearchMicrofluidic and Capillary Electrophoresis Applications

Cited by 182

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer

Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 129

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2016) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 98

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

Gambaro, K., Quinn, M. C., Cáceres-Gorriti, K. Y., Shapiro, R. S., Provencher, D., Rahimi, K., Mes-Masson, A.-M., & Tonin, P. N. (2015) · BMC Cancer

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 21